PDF(Pubmed)
Abstract：
BACKGROUND: Intralesional methotrexate injection (IL-MTX) is an appropriate strategy for treating epithelial crateriform tumors (ECTs) when surgical excision can result in functional or cosmetic defects; however, not all ECTs are responsive to this treatment.
OBJECTIVE: This study aimed to evaluate the effectiveness of IL-MTX for ECTs and to determine the differences in clinical response according to the pathological features.
METHODS: The medical records of patients treated with IL-MTX for their ECTs were retrospectively reviewed. Effectiveness was evaluated in terms of size reduction and flattening.
RESULTS: Twenty-five cases of ECTs with biopsy were included in this study. Eight cases of keratoacanthoma (KA) and 15 cases of squamous cell carcinoma (SCC) were identified, but 2 cases could not be clearly distinguished. Seventeen patients (68%) showed a response after injection, and response rate in KA and SCC were 75% (6/8) and 60% (9/15), respectively. Nine patients showed complete resolution with IL-MTX. Patients received 3 injections, and regression was observed in 7.56 weeks after the first injection. According to histopathological results, patients with KA and SCC received 2 and 3.33 injections, respectively, and complete resolution was observed after 7 and 7.67 weeks, respectively.
CONCLUSIONS: IL-MTX is safe and effective, and could be considered as a useful non-surgical treatment option for ECTs. Both KA and crateriform SCC showed good response; However, KA showed a better response.
OBJECTIVE: This study aimed to evaluate the effectiveness of IL-MTX for ECTs and to determine the differences in clinical response according to the pathological features.
METHODS: The medical records of patients treated with IL-MTX for their ECTs were retrospectively reviewed. Effectiveness was evaluated in terms of size reduction and flattening.
RESULTS: Twenty-five cases of ECTs with biopsy were included in this study. Eight cases of keratoacanthoma (KA) and 15 cases of squamous cell carcinoma (SCC) were identified, but 2 cases could not be clearly distinguished. Seventeen patients (68%) showed a response after injection, and response rate in KA and SCC were 75% (6/8) and 60% (9/15), respectively. Nine patients showed complete resolution with IL-MTX. Patients received 3 injections, and regression was observed in 7.56 weeks after the first injection. According to histopathological results, patients with KA and SCC received 2 and 3.33 injections, respectively, and complete resolution was observed after 7 and 7.67 weeks, respectively.
CONCLUSIONS: IL-MTX is safe and effective, and could be considered as a useful non-surgical treatment option for ECTs. Both KA and crateriform SCC showed good response; However, KA showed a better response.
摘要：
背景：当手术切除可能导致功能或美容缺陷时，甲氨蝶呤内注射（IL-MTX）是治疗上皮样肿瘤（ECT）的适当策略；但是，并非所有的ECT都对这种治疗有反应。
目的：本研究旨在评估IL-MTX对ECT的有效性，并根据病理特征确定临床反应的差异。
方法：回顾性分析使用IL-MTX治疗ECT患者的病历。在尺寸减小和展平方面评价有效性。
结果：本研究纳入了25例ECT活检病例。确定了8例角化棘皮瘤（KA）和15例鳞状细胞癌（SCC）。但2例无法明确区分。17名患者（68％）在注射后表现出反应，KA和SCC的反应率分别为75％（6/8）和60％（9/15），分别。9例患者显示IL-MTX完全消退。患者接受了3次注射，在第一次注射后7.56周观察到消退。根据组织病理学结果,KA和SCC患者接受2次和3.33次注射，分别,在7周和7.67周后观察到完全消退，分别。
结论：IL-MTX是安全有效的，并且可以被认为是ECT的一种有用的非手术治疗选择。KA和梭形SCC均表现出良好的反应；然而，KA表现出更好的反应。
目的：本研究旨在评估IL-MTX对ECT的有效性，并根据病理特征确定临床反应的差异。
方法：回顾性分析使用IL-MTX治疗ECT患者的病历。在尺寸减小和展平方面评价有效性。
结果：本研究纳入了25例ECT活检病例。确定了8例角化棘皮瘤（KA）和15例鳞状细胞癌（SCC）。但2例无法明确区分。17名患者（68％）在注射后表现出反应，KA和SCC的反应率分别为75％（6/8）和60％（9/15），分别。9例患者显示IL-MTX完全消退。患者接受了3次注射，在第一次注射后7.56周观察到消退。根据组织病理学结果,KA和SCC患者接受2次和3.33次注射，分别,在7周和7.67周后观察到完全消退，分别。
结论：IL-MTX是安全有效的，并且可以被认为是ECT的一种有用的非手术治疗选择。KA和梭形SCC均表现出良好的反应；然而，KA表现出更好的反应。
